A Prospective, Multicenter, Single-Arm Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Acute Lymphocytic Leukemia
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Enrollment
- 100
- Locations
- 5
- Primary Endpoint
- Number of participants with Adverse Events
- Last Updated
- 8 years ago
Overview
Brief Summary
Autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) will be infused back to patients with refractory /relapsed B cell malignancies, including lymphoma and leukemia. The patients will be monitored after infusion of anti-CD19 CAR-transduced T cells for safety,adverse events, persistence of anti-CD19 CAR-transduced T cells and treatment efficacy.
Detailed Description
Despite progress has been made to date in the treatment of patients with B cell malignancies, including leukemia and lymphoma, many patients with relapsed or refractory diseases do not respond to the standard treatments. It has been shown that anti-CD19 CAR-transduced T cells may be an effective approach to treat the relapsed or refractory diseases. The procedure involves collecting PBMCs from the patients and modifying the T cells to attack the malignant B cells. In this trial, autologous T cells engineered to express an anti-CD19 chimeric antigen receptor (CAR) containing the signaling domains of CD28 or 4-1BB and CD3-zeta will be infused back to patients with B cell malignancies, including lymphoma and leukemia. The patients will be pretreated with a lymphodepleting preconditioning regimen before the infusion of anti-CD19 CAR T cells, and will be monitored for safety, adverse events, persistence of anti-CD19 CAR-transduced T cells and the treatment efficacy.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patients must have a CD19+ B cell malignancy，including relapsed or refractory B cell leukemia and/or B cell lymphoma；
- •Patients must have a measurable or evaluable disease at the time of enrollment, which may include any evidence of disease including minimal residual disease detected by flow cytometry, cytogenetics, or polymerase chain reaction (PCR) analysis；
- •Patients with history of allogeneic stem cell transplantation are eligible, providing 6 months had elapsed from SCT, they have no evidence of active graft-versus-host disease (GVHD) and no longer taking immunosuppressive agents during the treatment;
- •Able to understand and sign the Informed Consent Document；
- •There is no obvious dysfunctions in heart , liver, lung, kidney, and performance status with ECOG \< 2；
- •Life expectancy：More than 3 months for leukemia and more than 6 months for lymphoma.
Exclusion Criteria
- •Patients that require urgent therapy due to tumor mass effects such as bowel obstruction or blood vessel compression；
- •Patients that have active hemolytic anemia；
- •Patients who have uncontrollable infectious diseases within 2 weeks before enrollment;
- •Patients with human immunodeficiency virus (HIV) antibody seropositive;
- •Active infection of Hepatitis B virus and / or hepatitis C virus;
- •Patients with any residual intracranial implants；
- •Coagulation disorders or other major medical illnesses of the cardiovascular, respiratory or immune system；
- •Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency Disease)；
- •Concurrent opportunistic infections；
- •Concurrent systemic steroid therapy；
Outcomes
Primary Outcomes
Number of participants with Adverse Events
Time Frame: 24 months
To evaluate the safety and feasibility of the administration of anti-CD19 CAR transduced T cells in patients with refractory /relapsed CD19+ B cell malignancies.
Number of participants with clinical responses
Time Frame: 24 months
To determine if the treatment regimen can result in clinical regression of B cell malignancies in the patients as described above.
Secondary Outcomes
- Evaluation of overall survial(24 months)